Assignee
ADVERUM BIOTECHNOLOGIES INC
US·11 granted patents·19 pending applications·29 citations·filing 2016–2024
Top patents by PatentIndex Score
30 records- 0195US11021519B2Compositions and methods for intravitreal delivery of polynucleotides to retinal conesADVERUM BIOTECHNOLOGIES INC·Filed 2016·Granted Jun 1, 2021·16 cites·24 claims
- 0289US11510950B2Variant AAV capsids for intravitreal deliveryADVERUM BIOTECHNOLOGIES INC·Filed 2020·Granted Nov 29, 2022·4 cites·32 claims
- 0389US11352644B2Compositions and methods for enhanced gene expressionADVERUM BIOTECHNOLOGIES INC·Filed 2020·Granted Jun 7, 2022·2 cites·17 claims
- 0486US11248214B2Compositions and methods for enhanced gene expression in cone cellsADVERUM BIOTECHNOLOGIES INC·Filed 2018·Granted Feb 15, 2022·2 cites·28 claims
- 0585US11192925B2Modified AAV capsids and uses thereofADVERUM BIOTECHNOLOGIES INC·Filed 2017·Granted Dec 7, 2021·2 cites·13 claims
- 0685US10584328B2Mutant viral capsid libraries and related systems and methodsADVERUM BIOTECHNOLOGIES INC·Filed 2016·Granted Mar 10, 2020·3 cites·20 claims
- 0780US2024301008A1Modified aav capsids and uses thereofADVERUM BIOTECHNOLOGIES INC·Filed 2024·Application pending·0 cites
- 0877US12275959B2Compositions and methods for enhanced gene expression in cone cellsADVERUM BIOTECHNOLOGIES INC·Filed 2021·Granted Apr 15, 2025·0 cites·16 claims
- 0976US2023257777A1Compositions and methods for enhanced gene expressionADVERUM BIOTECHNOLOGIES INC·Filed 2023·Application pending·0 cites
- 1075US12030914B2Modified AAV capsids and uses thereofADVERUM BIOTECHNOLOGIES INC·Filed 2021·Granted Jul 9, 2024·0 cites·13 claims
- 1169US2023322911A1Compositions and methods for reducing ocular neovascularizationADVERUM BIOTECHNOLOGIES INC·Filed 2022·Application pending·0 cites
- 1269US2026041791A1Compositions and methods for treatment of achromotopsiaADVERUM BIOTECHNOLOGIES INC·Filed 2023·Application pending·0 cites
- 1367US2025250547A1OPTIMIZATION OF HEK293 SUSPENSION PLATFORM FOR IMPROVED rAAV TITERSADVERUM BIOTECHNOLOGIES INC·Filed 2023·Application pending·0 cites
- 1466US2021388030A1Compositions and methods for intravitreal delivery of polynucleotides to retinal conesADVERUM BIOTECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 1565US2025360227A1Melanopsin variants for vision restorationADVERUM BIOTECHNOLOGIES INC·Filed 2023·Application pending·0 cites
- 1664US11773406B2Compositions and methods for enhanced gene expressionADVERUM BIOTECHNOLOGIES INC·Filed 2018·Granted Oct 3, 2023·0 cites·13 claims
- 1764US11427931B2Mutant viral capsid libraries and related systems and methodsADVERUM BIOTECHNOLOGIES INC·Filed 2020·Granted Aug 30, 2022·0 cites·16 claims
- 1864US2022265740A1Treatment of amd using aav2 variant with afliberceptADVERUM BIOTECHNOLOGIES INC·Filed 2021·Application pending·0 cites
- 1961US2024197915A1Methods of treating ocular diseases using aav2 variants encoding afliberceptADVERUM BIOTECHNOLOGIES INC·Filed 2022·Application pending·0 cites
- 2060US2019100582A1Compositions and methods for reducing ocular neovascularizationADVERUM BIOTECHNOLOGIES INC·Filed 2018·Application pending·0 cites
- 2160US2019151409A1Treatment of amd using aav2 variant with afliberceptADVERUM BIOTECHNOLOGIES INC·Filed 2018·Application pending·0 cites
- 2260US2026043046A1Cassettes of anti-complement component 3 antibody, vectorization and theraputic applicationADVERUM BIOTECHNOLOGIES INC·Filed 2023·Application pending·0 cites
- 2356US2025137011A1Methods of treating ocular neovascular diseases using aav2 variants encoding afliberceptADVERUM BIOTECHNOLOGIES INC·Filed 2023·Application pending·0 cites
- 2451US2022187310A1Anti-drug antibody assayADVERUM BIOTECHNOLOGIES INC·Filed 2022·Application pending·0 cites
- 2548US12385064B2Intravitreal dosing for delivery of polynucleotides to retinal conesADVERUM BIOTECHNOLOGIES INC·Filed 2022·Granted Aug 12, 2025·0 cites·8 claims
- 2647US2020297869A1Sequential intravitreal administration of aav gene therapy to contralateral eyesADVERUM BIOTECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 2744US2021100856A1Methods of treating ocular neovascular diseases using aav2 variants encoding afliberceptADVERUM BIOTECHNOLOGIES INC·Filed 2020·Application pending·0 cites
- 2842US2019142975A1Evasion of neutralizing antibodies by a recombinant adeno-associated virusADVERUM BIOTECHNOLOGIES INC·Filed 2017·Application pending·0 cites
- 2941US2021130413A1Modified aav capsids and uses thereofADVERUM BIOTECHNOLOGIES INC·Filed 2018·Application pending·0 cites
- 3036US2019154667A1Organotypic pig retina culture systemADVERUM BIOTECHNOLOGIES INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ADVERUM BIOTECHNOLOGIES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →